Abstract: SA-PO1176
Plasma Fibroblast Growth Factor 23 (FGF23) and Protein Alpha-1-Microglobulin/Bikunin Precursor (AMBP) as Predictors of Cardiovascular Disease (CVD) Endpoints in The Boston Kidney Biopsy Cohort (BKBC)
Session Information
- NIDDK KUH Summer Undergraduate Research Program Posters
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention
Author
Group or Team Name
- Debbie Adam. Harvard University, Cambridge, MA.
Background
Chronic Kidney Disease (CKD) is a risk factor for the development of Cardiovascular Disease (CVD). Research into nontraditional risk factors could help to provide more information as to why this complex relationship exists. Specifically, fibroblast growth factor 23 (FGF23) and protein α1-microglobulin/bikunin precursor (AMBP) have both shown promise as renal failure biomarkers in CVD-related clinical trials. From this knowledge, we hypothesized that elevated levels of plasma FGF23 and AMBP in CKD patients would demonstrate an accelerated time to CVD endpoint.
Methods
The population of interest were patients enrolled for a native kidney biopsy date between 2006 and 2018 at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH). Biological specimens were collected on all consented patients over the age of 18. Plasma FGF23 and protein AMBP were measured using multiplex immunoassay (inter-assay CV <10% for blind replicate samples). Univariate and multivariate regression models were generated to assess if plasma FGF23 and AMBP were predictors of CVD outcomes in CKD patients.
Results
Patients with the highest levels of plasma FGF23 had a 3.136 risk of reaching the composite CVD endpoint relative to patients with lower levels of plasma FGF23 (HR=3.136 (1.098-8.959), p<.05). Patients with mid-levels of plasma protein AMBP had a .312 risk of reaching the CVD endpoint(s) relative to patients with lower levels of plasma protein AMBP (HR=.312 (.122-.798), p<.05).
Conclusion
It can be inferred from our findings that plasma FGF23 can be used to predict cardiovascular outcomes in CKD patients, while the same cannot be said categorically for plasma protein AMBP.